Holen Sie sich die Stockscreener-App
8.605
11.61%
-1.125
Schlusskurs vom Vortag:
$9.73
Offen:
$9.35
24-Stunden-Volumen:
1.56M
Relative Volume:
0.26
Marktkapitalisierung:
$671.28M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-209.96M
KGV:
-2.7231
EPS:
-3.16
Netto-Cashflow:
$-176.27M
1W Leistung:
-7.82%
1M Leistung:
+81.82%
6M Leistung:
-14.08%
1J Leistung:
-27.73%
1-Tages-Spanne:
$8.52
$9.54
1-Wochen-Bereich:
$8.5499
$10.85
52-Wochen-Spanne:
$2.68
$17.00
Replimune Group Inc Stock (REPL) Company Profile
Firmenname
Replimune Group Inc
Sektor
Branche
Telefon
(781) 222-9600
Adresse
500 UNICORN PARK, WOBURN, MA
Vergleichen Sie REPL mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
REPL
Replimune Group Inc
|
8.60 | 759.48M | 0 | -209.96M | -176.27M | -3.16 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.06 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
642.70 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
446.89 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
829.01 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
184.11 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Replimune Group Inc Stock (REPL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-27 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2025-10-20 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2025-10-20 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2025-10-20 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2025-10-20 | Hochstufung | Wedbush | Neutral → Outperform |
| 2025-09-19 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2025-07-30 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
| 2025-07-23 | Herabstufung | BMO Capital Markets | Outperform → Underperform |
| 2025-07-23 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2025-07-23 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2025-07-22 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2025-07-22 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2025-07-22 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2025-07-22 | Herabstufung | Wedbush | Outperform → Neutral |
| 2025-06-20 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-08-28 | Eingeleitet | ROTH MKM | Buy |
| 2023-04-17 | Fortgesetzt | Piper Sandler | Overweight |
| 2021-11-19 | Eingeleitet | Piper Sandler | Overweight |
| 2021-10-15 | Fortgesetzt | BTIG Research | Buy |
| 2020-11-17 | Eingeleitet | BTIG Research | Buy |
| 2020-11-02 | Eingeleitet | Jefferies | Buy |
| 2020-10-15 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2020-07-01 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2020-05-05 | Eingeleitet | Barclays | Overweight |
| 2019-09-04 | Eingeleitet | ROTH Capital | Buy |
| 2019-07-23 | Eingeleitet | Chardan Capital Markets | Buy |
| 2019-07-12 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2019-07-08 | Eingeleitet | H.C. Wainwright | Buy |
| 2019-04-25 | Eingeleitet | Wedbush | Outperform |
| 2019-01-23 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2018-08-14 | Eingeleitet | JP Morgan | Overweight |
| 2018-08-14 | Eingeleitet | Leerink Partners | Outperform |
Alle ansehen
Replimune Group Inc Aktie (REPL) Neueste Nachrichten
REPL: Analyst Raises Price Target and Upgrades Rating to Market Perform | REPL Stock News - GuruFocus
Replimune Group Inc. stock volume spike explainedJobs Report & Free Technical Pattern Based Buy Signals - newser.com
What risks investors should watch in Replimune Group Inc. stockStop Loss & Short-Term High Return Strategies - newser.com
How to use Fibonacci retracement on Replimune Group Inc.July 2025 Volume & Daily Stock Trend Watchlist - newser.com
How Replimune Group Inc. stock compares to growth peers2025 Performance Recap & Fast Entry High Yield Tips - newser.com
Trend analysis for Replimune Group Inc. this weekTrade Ideas & Daily Stock Momentum Reports - newser.com
What recovery options are there for Replimune Group Inc.Volume Spike & Real-Time Price Movement Reports - newser.com
How to build a custom watchlist for Replimune Group Inc.Insider Selling & Technical Pattern Based Buy Signals - newser.com
Price momentum metrics for Replimune Group Inc. explainedMarket Rally & Consistent Growth Equity Picks - newser.com
Will Replimune Group Inc. stock benefit from AI adoptionWatch List & Trade Opportunity Analysis Reports - newser.com
What to do if you’re stuck in Replimune Group Inc.Market Sentiment Summary & Daily Price Action Insights - newser.com
Why Replimune Group Inc. stock is a must watch in 2025Trade Signal Summary & Daily Profit Maximizing Tips - newser.com
What hedge fund activity signals for Replimune Group Inc. stock2025 Market Sentiment & Weekly Stock Breakout Alerts - newser.com
Brokers Set Expectations for Replimune Group Q2 Earnings - MarketBeat
Is Replimune Group Inc. stock a buy before product launchesEarnings Recap Report & Long-Term Safe Investment Plans - newser.com
Replimune Group (NASDAQ:REPL) Stock Price Up 9.2% After Analyst Upgrade - MarketBeat
HC Wainwright Forecasts Replimune Group Q2 Earnings - MarketBeat
Replimune Group (REPL) Price Target Increased by 48.75% to 10.84 - Nasdaq
Traders Buy High Volume of Call Options on Replimune Group (NASDAQ:REPL) - MarketBeat
How Replimune Group Inc. stock reacts to Fed rate cuts2025 Year in Review & Fast Gaining Stock Reports - Fundação Cultural do Pará
Replimune Group, Inc. (NASDAQ:REPL) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Published on: 2025-10-27 17:22:37 - newser.com
Opinion | The Spin Doctors at the FDA - The Wall Street Journal
HC Wainwright Upgrades Replimune Group to Buy From Neutral, Price Target is $12 - MarketScreener
H.C. Wainwright upgrades Replimune stock rating to Buy on RP1 approval chances - Investing.com Canada
Finanzdaten der Replimune Group Inc-Aktie (REPL)
Umsatz
Nettogewinn
Free Cashflow
ENV
Replimune Group Inc-Aktie (REPL) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Astley-Sparke Philip | Director |
May 20 '25 |
Sale |
8.06 |
32,279 |
260,169 |
1,405,071 |
| Xynos Konstantinos | Chief Medical Officer |
May 20 '25 |
Sale |
8.06 |
7,952 |
64,093 |
146,933 |
| Schwendenman Andrew | Chief Accounting Officer |
May 20 '25 |
Sale |
8.05 |
3,287 |
26,460 |
68,284 |
| Patel Sushil | Chief Executive Officer |
May 20 '25 |
Sale |
8.06 |
25,105 |
202,346 |
343,576 |
| Hill Emily Luisa | Chief Financial Officer |
May 20 '25 |
Sale |
8.05 |
2,535 |
20,407 |
143,522 |
| Sarchi Christopher | Chief Commercial Officer |
May 20 '25 |
Sale |
8.05 |
3,749 |
30,179 |
128,296 |
| Patel Sushil | Chief Executive Officer |
Dec 16 '24 |
Sale |
12.42 |
10,000 |
124,200 |
202,014 |
0.09%
0.32%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):